Fresenius SE KGaAXSWX:FRE 71 Return-on-Tangible-Asset is 6.84% as of Mar. 2026, which is 40% above its 10-year median of 4.90. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF33.18 (Fairly Valued). The stock has 5 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Fresenius SE KGaA ranks better than 66.91% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Fresenius SE KGaA's annualizedNet Income for the quarter that ended in Mar. 2026 was CHF1,584 Mil. Fresenius SE KGaA's average total tangible assets for the quarter that ended in Mar. 2026 was CHF23,167 Mil. Therefore, Fresenius SE KGaA's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.84%.
The historical rank and industry rank for Fresenius SE KGaA's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:FRE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.74 Med: 4.9 Max: 7.77
Current: 5.81
During the past 13 years, Fresenius SE KGaA's highest Return-on-Tangible-Asset was 7.77%. The lowest was -1.74%. And the median was 4.90%.
XSWX:FRE's Return-on-Tangible-Asset is ranked better than 66.91% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs XSWX:FRE: 5.81
Fresenius SE KGaA (XSWX:FRE) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Fresenius SE KGaA Return-on-Tangible-Asset Related Terms
Fresenius SE KGaA Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.84% mean?
Fresenius SE KGaA (XSWX:FRE) has a Return-on-Tangible-Asset of 6.84% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fresenius SE KGaA and its competitors. This is 40% above median its historical median of 4.90. According to the industry distribution chart, Fresenius SE KGaA ranks #226 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 33.1%.
Is Fresenius SE KGaA's Return-on-Tangible-Asset too high?
Fresenius SE KGaA's current Return-on-Tangible-Asset of 6.84% is 40% above median its 10-year median of 4.90. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Fresenius SE KGaA's value of 6.84% is 181.5% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #226 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Return-on-Tangible-Asset compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #226 out of 683 companies for Return-on-Tangible-Asset. This puts Fresenius SE KGaA in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Fresenius SE KGaA's value of 6.84% is 181.5% above this benchmark. While the company's 10-year median is 4.90 vs. the industry median of 2.43, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Return-on-Tangible-Asset of 6.84% is 181.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Return-on-Tangible-Asset is 6.84%, which is 40% above median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF33.18, compared to a current price of CHF36.15 — trading 9% above its estimated fair value. The current Return-on-Tangible-Asset is 6.84%, which is 40% above median its 10-year median of 4.90 and 181.5% above the Healthcare Providers & Services industry median of 2.43. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Return-on-Tangible-Asset is 6.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF36.15 is trading 9% above its estimated GF Value™ of CHF33.18.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
Return-on-Tangible-Asset: 6.84% (40% above median its 10-year median of 4.90)
GF Value™: CHF33.18 vs. price of CHF36.15 (9% above fair value)
Industry Position: 181.5% above the Healthcare Providers & Services median (#226 of 683)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
